The First Study Evaluating Effectiveness and Safety of the Endoscopic Sleeve Gastroplasty in HIV Patients

Obes Surg. 2020 Mar;30(3):1159-1162. doi: 10.1007/s11695-020-04410-w.

Abstract

The authors evaluated, retrospectively, the endoscopic sleeve gastroplasty impact in seven HIV patients, regarding effectiveness and safety outcomes. The mean baseline body mass index (BMI) was 33.76 kg/m2. The mean baseline CD4+ cell count was 690.43 cells/mm3, and the baseline viral load was undetectable. After 6 months, absolute weight loss, percentage of excess weight loss, percentage total weight loss, and BMI reduction were 20.2 ± 2.6 kg, 85.5 ± 11.1%, 21.3 ± 2.4%, and 7.1 ± 0.8 kg/m2, respectively. No patients presented severe adverse events. After 6 months, the viral load remained undetectable and the mean CD4+ cell count was 710.57 cells/mm3. The endoscopic sleeve gastroplasty is an effective and safe procedure to perform in obese HIV patients.

Keywords: AIDS; Endoscopic therapy; Endoscopy; Gastroplasty; HIV; Infectiology; Obesity.

MeSH terms

  • Gastroplasty* / adverse effects
  • HIV Infections*
  • Humans
  • Obesity, Morbid* / surgery
  • Retrospective Studies
  • Treatment Outcome